You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GEJ adenocarcinoma

Showing 1 - 25 of 1,998
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction (GEJ) Cancer
  • T-Dxd(Trastuzmab deruxtecan), Ramucirumab
  • (no location specified)
Jun 7, 2023

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric

Available
  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer
  • +3 more
  • Morristown, New Jersey
    AMG Hematology/Oncology
Sep 15, 2023

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Tucson (Tadalafil 20 MG)

Not yet recruiting
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Tadalafil 20 MG
  • Tucson, Arizona
    Arizona Cancer Center at UMC North/University Medical Center
Feb 1, 2023

Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer Trial (TST001, CapOx or mFOLFOX6 and NIVO or (Substudy)

Not yet recruiting
  • Gastric Cancer
  • +2 more
  • TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
  • Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
  • (no location specified)
Oct 16, 2023

Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Trial in Guangzhou (zolbetuximab)

Completed
  • Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
  • Guangzhou, China
    Site CN86001
Jan 11, 2022

HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer
  • HER2-positive Gastroesophageal Junction Adenocarcinoma
  • Trastuzumab deruxtecan
  • (no location specified)
Aug 11, 2023

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Beijing (CS1001 mAb, CS1001 , Oxaliplatin)

Active, not recruiting
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • CS1001 monoclonal antibody
  • +3 more
  • Beijing, China
    Beijing Cancer Hospital
Sep 27, 2022

Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma Trial in Japan (ASP2138)

Recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • Santa Monica, California
  • +5 more
Dec 13, 2022

Gastric Cancer, Gastroesophageal-junction Cancer Trial in Wuhan, Nanjing, Taiyuan (Tislelizumab, S-1, Oxaliplatin)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Wuhan, Hubei, China
  • +2 more
Jan 16, 2023

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Trial in China (Trastuzumab Deruxtecan)

Recruiting
  • Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Trastuzumab Deruxtecan
  • Beijing, China
  • +25 more
Jul 27, 2022

HER2-positive Gastric Cancer Trial in United States (Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel,

Recruiting
  • HER2-positive Gastric Cancer
  • Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel
  • Cinrebafusp alfa (PRS-343) in combination with tucatinib
  • Santa Barbara, California
  • +3 more
Jan 14, 2022

Gastric Cancer, Peritoneal Metastases, Ascites, Malignant Trial in Hangzhou (Sintilimab in Combination With S-1/oxaliplatin With

Recruiting
  • Gastric Cancer
  • +2 more
  • Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion
  • Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 18, 2023

Adenocarcinoma - GEJ, Adenocarcinoma of the Stomach Trial in Bengbu (HER2 Tumor Vaccine, HER2 Tumor Vaccine+ Standard of Care

Recruiting
  • Adenocarcinoma - GEJ
  • Adenocarcinoma of the Stomach
  • HER2 Tumor Vaccine
  • HER2 Tumor Vaccine+ Standard of Care chemotherapy
  • Bengbu, Anhui, China
    First Affiliated Hospital Bengbu Medical College
Apr 6, 2022

Gastroesophageal Junction (GEJ) Adenocarcinoma Trial in Beijing (Q-1802 Injection,Oxaliplatin Injection,Capecitabine)

Recruiting
  • Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Q-1802 Injection,Oxaliplatin Injection,Capecitabine
  • Beijing, Beijing, China
    Beijing cancer hospical
Jul 27, 2023

Gastric Adenocarcinoma Trial (Pembrolizumab, Cisplatin, 5-FU)

Completed
Has Results
  • Gastric Adenocarcinoma
  • Pembrolizumab
  • +4 more
  • (no location specified)
Aug 18, 2022

HER2-positive Locally Advanced/Metastatic Gastric and/or

Not yet recruiting
  • Adenocarcinoma
    • Arkhangelsk, Russian Federation
    • +40 more
    May 29, 2023

    Gastric Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (Camrelizumab, Pyrotinib, Capecitabine)

    Not yet recruiting
    • Gastric Neoplasms
    • Gastroesophageal Junction Adenocarcinoma
    • Shanghai, China
      270 Dongan Road, Fudan University Shanghai Cancer Center
    Oct 27, 2021

    Gastric Cancer Trial in China (IN10018, Docetaxel)

    Completed
    • Gastric Cancer
    • Anyang, Henan, China
    • +7 more
    Nov 15, 2022

    Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Kashiwa (Trastuzumab Deruxtecan (T-DXd))

    Recruiting
    • Gastric Adenocarcinoma
    • Gastroesophageal Junction Adenocarcinoma
    • Trastuzumab Deruxtecan (T-DXd)
    • Kashiwa, Chiba, Japan
      National Cancer Center Hospital East
    Apr 5, 2022

    Metastatic HER2 Positive Gastroesophageal Junction Cancer Trial in La Jolla, Washington, Hackensack (CYNK-101, Pembrolizumab,

    Recruiting
    • Metastatic HER2 Positive Gastroesophageal Junction Cancer
    • CYNK-101
    • +6 more
    • La Jolla, California
    • +2 more
    Jul 12, 2022

    Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

    Active, not recruiting
    • Gastric or Gastroesophageal Junction Adenocarcinoma
    • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
    • Nanjing, Jiangsu, China
      Jiangsu Cancer Hospital
    Jul 4, 2023

    Gastric Cancer Trial in Seoul (pembrolizumab plus ramucirumab)

    Recruiting
    • Gastric Cancer
    • pembrolizumab plus ramucirumab
    • Seoul, Korea, Republic of
    • +1 more
    Feb 23, 2022

    Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer Trial (LB1908)

    Not yet recruiting
    • Gastric Cancer
    • +3 more
    • LB1908
    • (no location specified)
    Sep 9, 2022

    Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

    Not yet recruiting
    • Adenocarcinoma - GEJ
    • Gastric Adenocarcinoma
    • (no location specified)
    Sep 26, 2023

    Gastric Cancer, Gastroesophageal Junction Cancer Trial in China (Pembrolizumab, Placebo, Cisplatin)

    Recruiting
    • Gastric Cancer
    • Gastroesophageal Junction Cancer
    • Pembrolizumab
    • +7 more
    • Beijing, Beijing, China
    • +12 more
    Aug 17, 2022